Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
NASDAQ:GILD
Price:
67.01 USD
-0.95%
Market Closed
Updated:
May 16, 2024
Gilead Sciences Inc
Cost of Revenue
|
Gilead Sciences Inc
Cost of Revenue Peer Comparison
Comparables:
ABBV
AMGN
MRNA
VRTX
REGN
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$18.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-15%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$9.9B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-10%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Cost of Revenue
-$4B
|
CAGR 3-Years
-171%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-27%
|
See Also
What is Gilead Sciences Inc's Cost of Revenue?
Cost of Revenue
-6.6B
USD
-6.6B
USD
Based on the financial report for Mar 31, 2024, Gilead Sciences Inc's Cost of Revenue amounts to -6.6B USD.
What is Gilead Sciences Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-8%
-8%
Over the last year, the Cost of Revenue growth was -18%. The average annual Cost of Revenue growth rates for Gilead Sciences Inc have been -10% over the past three years , -7% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet
